MEDIPOST Co., Ltd. (KOSDAQ:078160)
10,340
-60 (-0.58%)
Aug 12, 2026, 3:30 PM KST
MEDIPOST Revenue
MEDIPOST had revenue of 19.46B KRW in the quarter ending March 31, 2026, with 1.24% growth. This brings the company's revenue in the last twelve months to 73.90B, up 2.85% year-over-year. In the year 2025, MEDIPOST had annual revenue of 73.66B with 4.25% growth.
Revenue (ttm)
73.90B
Revenue Growth
+2.85%
P/S Ratio
5.47
Revenue / Employee
229.49M
Employees
322
Market Cap
404.15B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.66B | 3.00B | 4.25% |
| Dec 31, 2024 | 70.66B | 2.01B | 2.93% |
| Dec 31, 2023 | 68.64B | 4.44B | 6.92% |
| Dec 31, 2022 | 64.20B | 9.34B | 17.03% |
| Dec 31, 2021 | 54.86B | 6.23B | 12.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Medy-Tox | 244.02B |
| BINEX | 164.00B |
| Onconic Therapeutics | 67.20B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |
| AbClon | 4.74B |
MEDIPOST News
- 3 months ago - Charles River (CRL) Partners with Medipost for Cell Therapy Advancements - GuruFocus
- 8 months ago - BDA Advises MEDIPOST on Growth Capital Raise - Benzinga